论文部分内容阅读
肿瘤细胞可表达肿瘤相关抗原(TAA),该抗原能开发用于诊断,也可作为免疫治疗的靶子。几乎每例结肠直肠癌的大部分肿瘤细胞表达有TAA CO17-1A。该抗原为非分泌的糖蛋白MW37KD。曾将鼠抗该抗原的单克隆抗体(McAb,IgG2A)用于治疗。在体内未偶合McAb介导的破坏肿瘤细胞的机制尚未完全明瞭。一般认为抗体依赖的细胞毒作用(ADCC)、补体溶解和抗-抗独特型抗体(ab3)的诱导作用较重要。用细胞抑制剂等不能治愈转移性结肠直肠癌,因此,需要有一种其它疗法。作者研究了患者单独应用McAb17-1A治疗这类患者的临
Tumor cells express tumor-associated antigen (TAA), which can be developed for diagnosis and can also be used as a target for immunotherapy. The majority of tumor cells in almost every case of colorectal cancer express TAA CO17-1A. This antigen is a non-secreted glycoprotein MW37KD. Mouse anti-antigen monoclonal antibodies (McAb, IgG2A) were used for treatment. The mechanism of uncoupled McAb-mediated destruction of tumor cells in vivo has not been fully understood. It is generally believed that antibody-dependent cytotoxicity (ADCC), complement lysis, and induction of anti-anti-idiotypic antibodies (ab3) are important. Metastatic colorectal cancer cannot be cured with cytostatic agents, etc. Therefore, there is a need for an alternative therapy. The authors studied the use of McAb17-1A alone to treat these patients.